Current Report Filing (8-k)
12 April 2023 - 10:31PM
Edgar (US Regulatory)
0001782107
false
0001782107
2023-04-12
2023-04-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 12, 2023
Blue
Water Vaccines Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41294 |
|
83-2262816 |
(State
or other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
201
E. Fifth Street, Suite 1900 Cincinnati,
Ohio | |
45202 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (513) 620-4101
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on Which Registered |
Common
Stock, par value $0.00001 per share |
|
BWV |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
On
April 12, 2023, Blue Water Vaccines Inc. (the “Company”) issued a press release announcing the signing of a Sponsored Research
Agreement with The University of Texas Health Science Center at San Antonio to initiate a non-human primate study for a live attenuated,
orally delivered chlamydia vaccine. A copy of the press release is attached hereto as Exhibit 99.1.
The
foregoing (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section
18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities
of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
Blue
Water Vaccines Inc. |
|
|
|
Date:
April 12, 2023 |
By: |
/s/
Joseph Hernandez |
|
|
Joseph
Hernandez |
|
|
Chief
Executive Officer |
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Oct 2023 to Oct 2024